Newcastle Clinical Trials Unit

Protect

Optimum therapy for thromboembolic complications after mitral valve repair

  • Study stage: Set-up
  • Sponsor: South Tees
  • Funder:  NIHR HTA
  • Therapeutic area: Cardiovascular